scispace - formally typeset
J

Jonathan Yen

Researcher at St. Jude Children's Research Hospital

Publications -  31
Citations -  1750

Jonathan Yen is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Stem cell & Haematopoiesis. The author has an hindex of 13, co-authored 22 publications receiving 1330 citations. Previous affiliations of Jonathan Yen include Novartis & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency-Associated Genes

TL;DR: It is reported here that butyrate, a naturally occurring fatty acid commonly used as a nutritional supplement and differentiation agent, greatly enhances the efficiency of induced pluripotent stem (iPS) cell derivation from human adult or fetal fibroblasts and provides an efficient method for reprograming various human adult somatic cells, including cells from patients that are more refractory to reprogramming.
Journal ArticleDOI

Generation of induced pluripotent stem cells in the absence of drug selection.

TL;DR: It is shown that n -myc can substitute for c-myc and that drug selection is dispensable for reprogramming of fibroblasts to pluripotent stem cells, and that the resulting induced pluripotency cells contribute extensively to teratomas and chimeras.
Journal ArticleDOI

Directed evolution of adenine base editors with increased activity and therapeutic application.

TL;DR: In primary human T cells, ABE8s achieve 98–99% target modification, which is maintained when multiplexed across three loci, and in human CD34 + cells, Abe8 can recreate a natural allele at the promoter of the γ-globin genes HBG1 and HBG2 with up to 60% efficiency.
Journal ArticleDOI

Selective in vivo metabolic cell-labeling-mediated cancer targeting

TL;DR: This work inhibits the cell-labeling activity of tetraacetyl-N-azidoacetylmannosamine (Ac4ManAz) by converting its anomeric acetyl group to a caged ether bond that can be selectively cleaved by cancer-overexpressed enzymes and thus enables the overexpression of azido groups on the surface of cancer cells.